Call for Abstract
Scientific Program
International Conference on Organ Donation and Transplantation Science, will be organized around the theme “Frontiers in Transplantation Science for Promising Future”
TRANSPLANTATION SCIENCE 2019 is comprised of 17 tracks and 50 sessions designed to offer comprehensive sessions that address current issues in TRANSPLANTATION SCIENCE 2019.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Skin Transplantation
- Track 1-2Kidney Transplantation
- Track 1-3Hair Transplantation
- Track 1-4Liver Transplantation
- Track 1-5Lung Transplantation
- Track 2-1Internal Organs: Kidneys, heart, liver, pancreas, intestines, lungs
- Track 3-1Liver Transplantation for Hepatitis B and C
- Track 3-2Surgical Innovations
- Track 3-3Immunosuppression
- Track 3-4Acute Liver Failure and Artificial Liver Support
- Track 4-1Living Donors and Deceased Donor
- Track 4-2Medical Complications
- Track 4-3Adult and Pediatric Transplants
- Track 4-4Hyper-Sensitization
- Track 5-1Bridge for Transplantation
- Track 5-2Artificial Heart
- Track 5-3Therapeutic and physiologic issues surrounding heart valve surgery
- Track 5-4Heart Regeneration
- Track 6-1Robotic Kidney Transplantation
- Track 6-2Minimal scarring
- Track 6-3Miniaturization
- Track 7-1Clinical Investigation
- Track 7-2Data Exclusivity
- Track 8-1Collagen injections
- Track 8-2Breast augmentation
- Track 8-3Lip reduction/Enhancement
- Track 8-4Voice modification surgery
- Track 9-1Multi-Organ Procurement
- Track 9-2Brain Death Diagnosis
- Track 9-3Thoracic and Mediastinal Inspection
- Track 10-1Allogeneic BMT
- Track 10-2Autologous BMT
- Track 11-1Acute repair surgery
- Track 11-2Reconstructive burn surgery
- Track 11-3Skin grafts
- Track 11-4Tissue expansion
- Track 11-5Microsurgery
- Track 12-1Hepatic Assist Techniques
- Track 12-2Hemodiabsorption
- Track 12-3Bio-artificial Liver Support Systems
- Track 13-1Hyper Acute Rejection
- Track 13-2Acute Rejection
- Track 13-3Chronic Rejection
- Track 14-1Living Donor Coordinator
- Track 14-2Organ Preservation Practitioner
- Track 14-3Recipient Centre Point of Contact
- Track 14-4Retrieving Surgeon
- Track 15-1Resource Allocation
- Track 15-2Reimbursement Mechanisms
\r\n The legislation called the Human Organ Act (THO) was passed in 1994 to streamline transplantation activities. Broadly, the act accepted brain death as a form of death and made the sale of kidney transplantations but also start other solid organ liver transplants, the organs have come from the deceased donor program as have all the hearts and pancreas transplants. In these states, a few hospitals along with committed NGOs have kept the momentum of the deceased ethics of unrelated programs and there seems to be a move towards making this an acceptable legal alternative. The ethics of commerce in organ donation and cloning, stem cells.
- Track 16-1Ethics of organ sale
Socioeconomic factors have been shown to affect health care outcomes. Poverty, unemployment, and low education level have been listed among the factors that adversely affect health.
Transplantation noncompliance: occupational status, educational level, language or cultural barriers, and ethnic background. Race and income have substantial effects on mortality and use of services among Medicare beneficiaries. Poor individuals are less likely than wealthy individuals to be medically suitable, to be interested in transplantation, and to complete the pre- transplantation workup
Based on UNOS data, in patients with liver transplant, it has been shown that neighbourhood income had no effect on graft or patient survival, education had only marginal influence on the outcome (survival was lower in those with a high school education than in those with graduate education), and patients with Medicaid and Medicare had lower survival when compared with those with private insurance .The results of our study that was done in kidney transplant recipients are similar. In the entire patient group, there is a statistically significant benefit to graft and patient survival from having private insurance compared with Medicare. This effect was observed across almost all racial groups (except for Asian patients, for whom there was no significant association between private insurance and graft survival). HMO/PPO was associated with significantly higher risk for graft failure but improved patient survival. These results are similar to those reported in liver transplant recipients.